zanidatamab,pembrolizumab
roche,jazz pharma,merck,beigene,zymeworks
[]
$bgne $jazz $mrk $rhhby $zyme asco-gi 2023 keytruda looms over zanidatamab's second shot 
News and analysis of biomedical, biopharma, biotech, biosciences, pharmaceutical, and technology equities